What Tesamorelin is

Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone–releasing hormone (GHRH) bearing a trans-3-hexenoyl moiety on the N-terminal tyrosine that confers resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage and extends in vivo half-life relative to native GHRH. The compound (also known by the development code TH9507) was characterized in the 2000s and is approved by the U.S. Food and Drug Administration under the brand name Egrifta (and later Egrifta SV) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (Falutz et al., 2007 — PMID 18057338). On this site Tesamorelin is discussed exclusively in the context of mechanism-based, non-clinical research on the GH/IGF-1 axis and visceral adiposity; nothing here is therapeutic guidance.

Mechanism of action

Tesamorelin binds the GHRH receptor on anterior pituitary somatotrophs and stimulates pulsatile GH secretion through the canonical GHRHR-Gαs-cAMP-PKA-CREB signaling axis, restoring or augmenting endogenous GH pulse amplitude. Increased GH stimulates hepatic IGF-1 production and engages downstream tissue effects of the GH/IGF-1 axis. Importantly, because the peptide acts at the hypothalamic-pituitary level rather than as exogenous GH, GH release remains physiologically pulsatile and remains subject to negative feedback by IGF-1 and somatostatin. Pre-clinical and clinical work has documented selective reduction in visceral adipose tissue without significant change in subcutaneous fat, attributed to the lipolytic action of restored GH pulses on metabolically active visceral depots (Falutz et al., 2007 — PMID 18057338).

Historical & structural context

Tesamorelin was developed by Theratechnologies as a stabilized GHRH analog for the specific clinical problem of HIV-associated lipodystrophy, in which antiretroviral therapy and HIV-related metabolic changes produce excess visceral adipose accumulation. The molecule's design centered on N-terminal modification of GHRH(1–44) with a trans-3-hexenoic acid moiety that blocks DPP-IV cleavage at the Tyr1-Ala2 bond, the principal proteolytic vulnerability of native GHRH. The peptide retains GHRHR pharmacology but achieves clinically useful exposure with once-daily subcutaneous administration. FDA approval was granted in 2010 based on Phase III data showing approximately 15% reduction in visceral adipose tissue at 26 weeks.

Methodological considerations

Researchers using tesamorelin should account for (1) the importance of N-terminal acyl-group integrity — exposure to esterases or extreme pH can hydrolyze the modification and restore DPP-IV vulnerability; (2) the difference between IGF-1 elevation as a pharmacodynamic readout (rapid) and visceral-adipose response (multi-week timescale); (3) inter-subject variability in baseline GH-axis sensitivity, which substantially affects measured response amplitude; (4) the appropriate imaging modality for visceral-fat quantification — single-slice CT or MRI at L4–L5 has been the field standard, while DEXA estimates are less specific; (5) glucose-tolerance monitoring, since GH-axis activation can transiently affect insulin sensitivity in pre-clinical and clinical studies.

Research applications

Non-clinical and translational research uses of tesamorelin have included:

Mechanistic studies of GHRH-receptor pharmacodynamics and DPP-IV-resistant peptide design (Falutz et al., 2010 — PMID 20554713).
Investigations of visceral-adipose-tissue biology and ectopic-fat metabolism, including hepatic and intramyocellular lipid (Stanley et al., 2014 — PMID 25038357).
Cognitive and CNS-aging studies in older adults exploring GH/IGF-1 effects on executive function (Baker et al., 2012 — PMID 22869065).
Cardiometabolic biomarker profiling (triglyceride, adiponectin, hsCRP).
HIV-associated nonalcoholic fatty liver disease (NAFLD) investigations (Stanley et al., 2019 — PMID 31611037).

Stability & handling notes

Lyophilized tesamorelin is typically stable at −20 °C for 24 months. Reconstituted solutions in sterile or bacteriostatic water are stored at 2–8 °C and protected from light; clinical-formulation labeling indicates use within hours of reconstitution under controlled conditions, but research stocks aliquoted at −20 °C maintain activity longer. The N-terminal acyl modification is the basis for DPP-IV resistance and must not be hydrolyzed; avoid acidic or alkaline buffers outside pH 4–7.

Common research dosing reference

Published clinical-pharmacology studies of tesamorelin used 1–2 mg subcutaneously once daily in adult cohorts. These figures are research benchmarks only and have no implication for off-label or non-indicated use; the FDA-approved labeling addresses one specific indication and is not generalizable.

Quality & specifications

Reference-grade material is typically characterized by reverse-phase HPLC purity ≥98%, electrospray-ionization mass spectrometry (ESI-MS) confirming the expected monoisotopic mass, and quantitative amino-acid analysis where applicable. Cell-culture-grade lots additionally include endotoxin testing by Limulus amebocyte lysate (LAL) assay and bioburden screening. Each lot is shipped with a Certificate of Analysis itemizing purity, identity, residual solvents, water content (Karl Fischer), and acetate or trifluoroacetate counter-ion content where relevant. Investigators evaluating new lots should request raw chromatograms and mass spectra prior to incorporation into published work.

Pharmacology in context

Tesamorelin sits within the small set of clinically validated GHRH analogs alongside sermorelin and the investigational CJC-1295. Unlike CJC-1295, tesamorelin is approved by the FDA for a specific clinical indication and has substantial Phase III safety and efficacy data in that population. Its pharmacology — DPP-IV-resistant N-terminal modification preserving GHRHR engagement while permitting once-daily subcutaneous administration — represents a successful application of medicinal-chemistry stabilization to a peptide previously limited by rapid clearance. Comparative work against CJC-1295 (DAC), sermorelin, and recombinant GH continues to inform mechanistic understanding of pulsatile GH-axis pharmacology.

Reporting & reproducibility expectations

Research-context publications using tesamorelin should report: (a) supplier, lot, HPLC purity, and mass-spec verification confirming N-terminal acyl modification; (b) reconstitution buffer and storage history; (c) clear separation of mechanism-of-action research questions from any therapeutic implications, given that this peptide has an FDA-approved indication that should not be conflated with off-label or research uses; (d) IGF-1 sampling at appropriate timepoints; (e) for body-composition studies, imaging modality and standardized landmarks; (f) baseline GH-axis assessment (peak GH on stimulation testing, basal IGF-1) for context.

Compliance & regulatory framing

This material is provided strictly for research and educational reference. The compound is supplied for in vitro investigation and laboratory characterization only and is not intended for human ingestion, injection, topical use, or any clinical application. Federal and state law treats research peptides as non-therapeutic chemicals; recipients are responsible for compliance with all applicable institutional, state, and federal regulations governing handling, storage, and disposal. Pricing, availability, and supply specifications are subject to change without notice. Request a Certificate of Analysis (COA), HPLC chromatograms, mass-spec verification, or compliance documentation from the Clinical Advisory Team for any specific lot.

Related research compounds

Researchers studying GHRH analogs and the GH/IGF-1 axis often co-reference CJC-1295 for the long-acting GHRH analog series, Ipamorelin for the GHS-R1a comparator, and AOD-9604 5 mg for GH-fragment lipolytic biology.

Sourcing & analytical verification

Research-context tesamorelin should be supplied with HPLC chromatograms confirming purity, mass-spec verification of the modified 44-residue peptide including the trans-3-hexenoyl N-terminal modification, and documentation of any salt forms or excipients. Verification of the N-terminal acyl group is particularly important, since hydrolysis of this modification reverts the peptide to a DPP-IV-vulnerable species with markedly different pharmacokinetics. Endotoxin testing is required for cell-culture or in vivo work. Investigators should be explicit about the difference between research-context use of tesamorelin in mechanistic studies and the FDA-approved clinical product, which is supplied through licensed pharmacies under specific labeling for a specific indication.

References

References below are anchor PubMed citations. Readers are encouraged to verify each in the National Library of Medicine database before using as a research source.

For Research Use Only. Not for human or veterinary consumption, diagnostic procedures, or therapeutic use. Content is educational and non-promotional.

Tesamorelin 15mg – GHRH Analog & VAT Research Peptide